- Dick’s Sporting Goods lays off 478 PGA golf pros
- Senators: Cease-fire must allow Israel to defend against rockets, tunnels
- Sierra Leone doctor fighting Ebola catches disease
- Iraq welcomes Russian fighter jets, helicopter gunships into ISIL fight
- John McCain laments: Obama’s ‘self-pity … is really kind of sad’
- GOP offer to fix VA gives $10 billion in emergency funds
- Paul Ryan offers to repair U.S. economic safety net with a single grant stream
- Kim Jong-un builds bond with Putin: $250M Russia-backed addition to key port opens
- Pope Francis meets Meriam Ibrahim, a Sudanese woman sentenced to death
- Detroit porch shooting trial: Suspect says he didn’t know gun was loaded
FDA says breast cancer drug did not extend lives
Question of the Day
WASHINGTON (AP) - Federal health scientists said Friday that follow-up studies of a Roche breast cancer drug showed that it failed extend patient lives, opening the door for it to be potentially withdrawal for use in treating that disease.
The Food and Drug Administration approved Roche’s blockbuster Avastin in 2008 based on a trial showing it slowed growth of tumors caused by breast cancer. The decision was controversial because drugs for cancer patients who have never been treated before must usually show evidence they extend lives.
Avastin’s so-called “accelerated approval” was based on the condition that later studies would show a survival benefit.
Additionally, the FDA said that in follow-up studies the drug did not slow tumor growth to the same degree as in earlier studies.
Patients taking Avastin showed significantly more side effects, including high blood pressure, fatigue and abnormal white blood cell levels.
The FDA has the option to remove drug’s approval for breast cancer.
Avastin is also approved for colon, lung, kidney and brain cancer. The drug was Roche’s top-selling cancer treatment last year with global sales of $5.9 billion.
Roche is headquartered in Basel, Switzerland, and its biotech unit Genentech is based in South San Francisco.
Avastin was the first drug to fight cancer by stopping nutrients from reaching tumors. Such “targeted therapies” were thought to hold promise for eliminating chemotherapy, but the two approaches are now used in combination.
Since 1992, the FDA has granted accelerated approval to drugs based on so-called surrogate endpoints, or initial measures that suggest the drug will make real improvements in patient health. For cancer drugs, tumor shrinkage is considered a predictor of increased survival.
Drugmakers favor the program because it helps them get products to market sooner.
But the program has not escaped criticism from government watchdogs.
Last fall the Government Accountability Office issued a report saying the FDA should do more to track whether drugs approved based on preliminary results actually have live up to their promise.
TWT Video Picks
The subsidies are a hit with patients who don't exist
- Hamas rejects Kerry's call for cease-fire; Fears grow others could join fight against Israel
- 'We're coming for you, Barack Obama': Top U.S. official discloses threat from ISIL terrorists
- Algerian plane diverted due to storms, second aircraft: 116 missing
- Obama's empty tough-talk: Gun prosecutions plummet on his watch
- House panel OKs resolution to sue president for Obamacare delays
- Conservative groups decry Democrats' 'war on women' tactic
- Obama says public not familiar enough with issues
- Evidence shows Russia firing artillery into Ukraine: Pentagon
- Astronaut shares 'saddest photo' from space: Bombs bursting over Israel, Gaza
- Doctor, 2 others shot at Pennsylvania hospital: reports
Obama's biggest White House 'fails'
Celebrities turned politicians
Athletes turned actors
20 gadgets that changed the world
Fighting in Iraq